Analysis of low-frequency mutations associated with drug resistance to raltegravir before antiretroviral treatment

Antimicrobial Agents and Chemotherapy

Volumn 55, Issue 3, 2011, Pages 1114-1119

  Liu, Jia ^a,c   Miller, Michael D ^b   Danovich, Robert M ^b   Vandergrift, Nathan ^a   Cai, Fangping ^a   Hicks, Charles B ^a   Hazuda, Daria J ^b   Gao, Feng ^a  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

^b MERCK RESEARCH LABORATORIES   (United States)

^c PEKING UNIVERSITY HEALTH SCIENCE CENTER   (China)

Author keywords

[No Author keywords available]

Indexed keywords

INTEGRASE; RALTEGRAVIR; VIRUS RNA;

ANTIVIRAL THERAPY; ARTICLE; CONTROLLED STUDY; GENETIC PROCEDURES; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; LINKAGE ANALYSIS; MUTATION RATE; PARALLEL ALLELE SPECIFIC SEQUENCING; PRIORITY JOURNAL; TREATMENT FAILURE; TREATMENT OUTCOME; VIRUS GENE; VIRUS LOAD; VIRUS MUTATION; VIRUS RESISTANCE;

ANTI-HIV AGENTS; DRUG RESISTANCE, VIRAL; HIV INFECTIONS; HUMANS; MUTATION; PYRROLIDINONES;

EID: 79952323624     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.01492-10     Document Type: Article

References (25)

1. Cai, F., et al. 2007. Detection of minor drug-resistant populations by parallel allele-specific sequencing. Nat. Methods 4:123-125.
2. Ceccherini-Silberstein, F., et al. 2010. Secondary HIV-1 integrase resistance mutations, found as minority quasispecies in integrase therapy naive patients, have little or no effect on susceptibility to integrase inhibitors. Antimicrob. Agents Chemother. 54:3938-3948.
3. Charpentier, C., et al. 2010. High frequency of integrase Q148R minority variants in HIV-infected patients naive of integrase inhibitors. AIDS 24:867-873.
4. Colgrove, R., and A. Japour. 1999. A combinatorial ledge: reverse transcriptase fidelity, total body viral burden, and the implications of multiple-drug HIV therapy for the evolution of antiviral resistance. Antiviral Res. 41:45-56. (Pubitemid 29132817)
5. Cooper, D. A., et al. 2008. Subgroup and resistance analyses of raltegravir for resistant HIV-1 infection. N. Engl. J. Med. 359:355-365.
6. Delelis, O., et al. 2009. The G140S mutation in HIV integrases from raltegravir-resistant patients rescues catalytic defect due to the resistance Q148H mutation. Nucleic Acids Res. 37:1193-1201.
7. Delelis, O., et al. 2010. Impact of Y143 HIV-1 integrase mutations on resistance to raltegravir in vitro and in vivo. Antimicrob. Agents Chemother. 54:491-501.
8. Fransen, S., et al. 2009. Loss of raltegravir susceptibility by human immunodeficiency virus type 1 is conferred via multiple nonoverlapping genetic pathways. J. Virol. 83:11440-11446.
9. Gao, F., and D. Wang. 2007. Minor drug-resistant HIV populations and treatment failure. Future Virol. 2:293-302. (Pubitemid 46813433)
10. Hicks, C., and R. M. Gulick. 2009. Raltegravir: the first HIV type 1 integrase inhibitor. Clin. Infect. Dis. 48:931-939.
11. Johnson, J. A., et al. 2008. Minority HIV-1 drug resistance mutations are present in antiretroviral treatment-naive populations and associate with reduced treatment efficacy. PLoS Med. 5:e158.
12. Lataillade, M., J. Chiarella, and M. J. Kozal. 2007. Natural polymorphism of the HIV-1 integrase gene and mutations associated with integrase inhibitor resistance. Antivir. Ther. 12:563-570.
13. Low, A., et al. 2009. Natural polymorphisms of human immunodeficiency virus type 1 integrase and inherent susceptibilities to a panel of integrase inhibitors. Antimicrob. Agents Chemother. 53:4275-4282.
14. Malet, I., et al. 2008. Mutations associated with failure of raltegravir treatment affect integrase sensitivity to the inhibitor in vitro. Antimicrob. Agents Chemother. 52:1351-1358.
15. Métifiot, M., C. Marchand, K. Maddali, and Y. Pommier. 2010. Resistance to integrase inhibitors. Viruses 2:1347-1366.
16. Metzner, K. J., et al. 2009. Minority quasispecies of drug-resistant HIV-1 that lead to early therapy failure in treatment-naive and -adherent patients. Clin. Infect. Dis. 48:239-247.
17. Miller, M. D., R. M. Danovich, and M. Witmer. 2009. Emerging patterns of resistance to integrase inhibitors, abstr. 125. 16th Conf. Retrovir. Opportunistic Infect.
18. Myers, R. E., and D. Pillay. 2008. Analysis of natural sequence variation and covariation in human immunodeficiency virus type 1 integrase. J. Virol. 82:9228-9235.
19. Quercia, R., E. Dam, D. Perez-Bercoff, and F. Clavel. 2009. Selective-advantage profile of human immunodeficiency virus type 1 integrase mutants explains in vivo evolution of raltegravir resistance genotypes. J. Virol. 83:10245-10249.
20. Rhee, S. Y., et al. 2008. Natural variation of HIV-1 group M integrase: implications for a new class of antiretroviral inhibitors. Retrovirology 5:74.
21. Shafer, R. W. 2009. Low-abundance drug-resistant HIV-1 variants: finding significance in an era of abundant diagnostic and therapeutic options. J. Infect. Dis. 199:610-612.
22. Simen, B. B., et al. 2009. Low-abundance drug-resistant viral variants in chronically HIV-infected, antiretroviral treatment-naive patients significantly impact treatment outcomes. J. Infect. Dis. 199:693-701.
23. Steigbigel, R. T., et al. 2008. Raltegravir with optimized background therapy for resistant HIV-1 infection. N. Engl. J. Med. 359:339-354.
24. Svarovskaia, E. S., et al. 2007. Low-level K65R mutation in HIV-1 reverse transcriptase of treatment-experienced patients exposed to abacavir or didanosine. J. Acquir. Immune Defic. Syndr. 46:174-180.
25. Van Laethem, K., et al. 1999. Phenotypic assays and sequencing are less sensitive than point mutation assays for detection of resistance in mixed HIV-1 genotypic populations. J. Acquir. Immune Defic. Syndr. 22:107-118.